Bulevirtide

Summary

Bulevirtide (CHEMBL4297711) is an approved protein (ATC J05AX28) targeting SLC10A1; indicated across 6 conditions including viral infectious disease and chronic hepatitis c virus infection.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: J05AX28
• Targets: 1 (SLC10A1)
• Indications: 6 conditions
• Clinical trials: 17

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297711
Name	Bulevirtide
Type	Protein
Max phase	4
ATC	J05AX28

Also known as: 915207G, Bulevirtida, Bulevirtide, Hepcludex, Hepcludextm, Myrcludex, BULEVIRTIDE

Parent form; salt/anhydrous children: CHEMBL5315080

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
SLC10A1	Sodium/bile acid and sulphated solute cotransporter 1	Binding		0.1%	Q14973

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): SLC10A1.

Top Reactome pathways

1 total, by targets touching each:

Pathway	Targets	Genes
Recycling of bile acids and salts	1	SLC10A1

Dominant GO biological processes

GO term	Targets
bile acid and bile salt transport	1
response to nutrient levels	1
response to estrogen	1
response to ethanol	1
cellular response to xenobiotic stimulus	1
monoatomic ion transport	1
sodium ion transport	1
lipid transport	1
symbiont entry into host cell	1
transmembrane transport	1

Indications & clinical

Indications

6 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
viral infectious disease	4	MONDO:0005108	EFO:0000763
chronic hepatitis C virus infection	3	MONDO:0005354	EFO:0004220
hepatitis D virus infection	2	MONDO:0005789	EFO:0007304
hepatitis B virus infection	2	MONDO:0005344	EFO:0004197
liver disorder	1	MONDO:0005154	HP:0001392

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 17.

Phase distribution

Phase	Trials
Not specified	10
PHASE3	2
PHASE2	2
PHASE1	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07128550	PHASE3	RECRUITING	A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide
NCT07454837	PHASE2/PHASE3	RECRUITING	Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide
NCT03852719	PHASE3	COMPLETED	Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD)
NCT07142811	PHASE2	ACTIVE_NOT_RECRUITING	A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection
NCT03852433	PHASE2	COMPLETED	Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)
NCT05760300	PHASE1	COMPLETED	A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function
NCT05765344	PHASE1	COMPLETED	Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function
NCT04863703	Not specified	ACTIVE_NOT_RECRUITING	Improvement of Portal Hypertension During Viral Suppression in Patients With Hepatitis Delta (IMPHROVE-D)
NCT05718700	Not specified	ACTIVE_NOT_RECRUITING	Study of Bulevirtide in Participants With Chronic Hepatitis D Infection
NCT06051045	Not specified	RECRUITING	Study to Evaluate Efficacy, Safety and Biomarkers of Bulevirtide Treatment in Chronic Hepatitis D Patients
NCT06122285	Not specified	RECRUITING	Effectiveness and Safety of Bulevirtide (BLV) Therapy in Patients With Chronic Hepatitis Delta (CHD) in Italy (D-SHIELD)
NCT06397859	Not specified	RECRUITING	Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis
NCT06504485	Not specified	RECRUITING	Immunological and Virological Characterization of Patients With Chronic HBV-HDV Infection: Outcomes and Response to Bulevirtide Treatment
NCT06780579	Not specified	AVAILABLE	Expanded Access for Bulevirtide
NCT07491848	Not specified	RECRUITING	Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D
NCT05928000	Not specified	UNKNOWN	HEllenic Multicenter ReAl-life CLInical Study for Bulevirtide Therapy in Chronic Hepatitis D: HERACLIS-BLV
NCT05962307	Not specified	COMPLETED	Efficacy and Safety of Bulevirtide (BLV) Therapy in HDV Chronic Hepatitis (CHD) in Italy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

24 molecules share ≥1 primary target. Top 24 by shared-target count:

Molecule	Source	Status	Shared targets
CYCLOSPORINE	ChEMBL + PubChem	Phase 4 (approved)	SLC10A1
EZETIMIBE	ChEMBL + PubChem	Phase 4 (approved)	SLC10A1
FUROSEMIDE	ChEMBL + PubChem	Phase 4 (approved)	SLC10A1
IRBESARTAN	ChEMBL + PubChem	Phase 4 (approved)	SLC10A1
PROPRANOLOL	ChEMBL + PubChem	Phase 4 (approved)	SLC10A1
RITONAVIR	ChEMBL + PubChem	Phase 4 (approved)	SLC10A1
ROSIGLITAZONE	ChEMBL + PubChem	Phase 4 (approved)	SLC10A1
URSODIOL	ChEMBL + PubChem	Phase 4 (approved)	SLC10A1
ZAFIRLUKAST	ChEMBL + PubChem	Phase 4 (approved)	SLC10A1
FLUVASTATIN	ChEMBL	Phase 4 (approved)	SLC10A1
SULFASALAZINE	ChEMBL	Phase 4 (approved)	SLC10A1
CURCUMIN	ChEMBL + PubChem	Phase 3 (approved)	SLC10A1
FASIGLIFAM	ChEMBL	Phase 3	SLC10A1
TIRATRICOL	ChEMBL	Phase 3	SLC10A1
LEVOPROPRANOLOL	ChEMBL	Phase 2	SLC10A1
Adefovir Dipivoxil	PubChem	Approved	SLC10A1
Bosentan	PubChem	Approved	SLC10A1
Bumetanide	PubChem	Approved	SLC10A1
Caspofungin	PubChem	Approved	SLC10A1
chenodiol	PubChem	Approved	SLC10A1
Deoxycholic Acid	PubChem	Approved	SLC10A1
Macitentan	PubChem	Approved	SLC10A1
Olmesartan	PubChem	Approved	SLC10A1
Progesterone	PubChem	Approved	SLC10A1